WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871 Million in the...

Related Keywords

Shanghai ,China ,Switzerland ,Germany ,Qidong ,Guangdong ,Couvet ,Switzerland General ,United States ,Wuxi ,Jiangsu ,Suzhou ,Hong Kong ,America ,Asia Pacific ,Davy Wu ,Ruijia Tang ,Manufacturing Organization ,Lab Testing Services Drive Steady Growth ,Accounting Standard For Business Enterprises ,Shanghai Stock Exchange ,National Medical Products Administration ,Site Management Organization ,International Financial Reporting Standards ,Owners Of The Company ,Contract Research ,Stock Exchange Of Hong Kong ,Second Quarter ,First Half ,Profit Attributable ,First Half Increased ,Turned Positive ,Stock Exchange ,Wuxi Apptec ,Accounting Standard ,Business Enterprises ,Contract Testing ,Model Drives Steady Growth ,Continued Expansion ,New Modalities ,Clinical Business Fully ,Wuxi Testing ,Strong Contribution ,Early Discovery Screening Platform Continued ,Generate Downstream ,Wuxi Biology ,Model Drives ,Tumor Infiltrating Lymphocyte ,Lenti Viral Vector ,Drug Inspection ,First Year ,Receive New Drug Application ,New Drugs Developed ,First Royalty ,Trial Approvals ,Financial Position ,Net Profit Attributable ,North America ,